Key result
Elevated serum NGAL (>157.35 ng/ml) and urinary AGT (>14.31 ng/ml) were associated with a 13.1-fold and 32.8-fold increased risk of acute kidney injury in patients with acute decompensated heart failure.
Why the study?
Early diagnosis of acute kidney injury is an urgent clinical problem in patients with acute decompensation of chronic heart failure.
Do biomarkers (NGAL, CysC, KIM-1, AGT) accurately diagnose acute kidney injury in patients with acute decompensation of chronic heart failure?
Observational (n=60)
No
Do biomarkers (NGAL, CysC, KIM-1, AGT) accurately diagnose acute kidney injury in patients with acute decompensation of chronic heart failure?
Serum NGAL and Cystatin C, and urine KIM-1 and AGT are highly sensitive and specific biomarkers for the early diagnosis of acute kidney injury in patients with acute decompensated heart failure.
May support early AKI risk stratification via NGAL/AGT in ADHF; leaves open need for prospective outcome trials before adoption.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nasonova et al. (2019) conducted an observational in Acute decompensation of chronic heart failure (n=60). Biomarkers of acute kidney injury (NGAL, CysC, KIM-1, AGT) vs. Patients without acute kidney injury was evaluated on Acute kidney injury (AKI) (OR 13.1, 95% CI 1.365-126.431, p=0.026). Elevated serum NGAL (>157.35 ng/ml) and urinary AGT (>14.31 ng/ml) were associated with a 13.1-fold and 32.8-fold increased risk of acute kidney injury in patients with acute decompensated heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: